DIACTANE Ge 200 mg

Generic drug from Praxilene
Therapeutic class: Cardiology and angiology
Active ingredients: Naftidrofuryl
laboratory: Menarini

Coated tablet
Box of 20
All forms


Symptomatic treatment of intermittent claudication of chronic occlusive arterial diseases of the lower limbs (stage 2).

Dosage DIACTANE Ge 200 mg Film-coated tablet Box of 20


Oral way.

· Arteriopathies of the lower limbs: 1 tablet, 3 times daily, or 600 mg of naftidrofuryl.

Treatment with naftidrofuryl has only a symptomatic effect, allowing a moderate improvement in walking distance within 6 months after initiation of treatment. It is of interest only in addition to other therapies or measures recommended in stage 2 AOMIs (management of cardiovascular risk factors, regular physical exercise, smoking cessation in particular).

The response to treatment should be re-evaluated after 6 months and its continuation reconsidered in the absence of improvement.

Administration mode

The catches will be distributed during meals.

Swallow the tablets without chewing, always with a large glass of water.

Against indications

Hypersensitivity to naftidrofuryl or any of the excipients

· Known hypoxaluria

· History of recurrent renal calcium lithiasis.

Adverse effects Diactane GE

Gastrointestinal disorders

· Digestive disorders (diarrhea, vomiting, epigastric pain).

· In some patients who took the drug without a drink at bedtime, discontinuation of the tablet resulted in local esophagitis.

· Cases of ulceration of the oral mucosa have been reported.

Hepatobiliary disorders

· Cases of severe hepatic impairment, of the acute cytolytic type, have been reported (see Warnings and Precautions ).

Renal and urinary disorders

· Renal calcium oxalic acid (see Warnings and Precautions ) section.

Skin and subcutaneous tissue disorders

· Rashes.

Reporting of suspected adverse reactions

The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Health professionals declare any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (Ansm) and the network of Regional Pharmacovigilance Centers - Website: www.ansm.sante.fr.

Popular Posts